baclofen and Pyrosis
baclofen has been researched along with Pyrosis in 10 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The intensity of heartburn symptom in response to esophageal acid infusion was significantly greater with baclofen than the placebo (P = 0." | 9.30 | Gamma-aminobutyric acid receptor type B agonist baclofen inhibits acid-induced excitation of secondary peristalsis but not heartburn sensation. ( Chen, CL; Hung, JS; Lei, WY; Liu, TT; Wong, MW; Yi, CH, 2019) |
| "Arbaclofen placarbil is a pro-drug of the gamma-aminobutyric acid-B agonist R-baclofen that has been shown to reduce reflux episodes in patients with gastro-oesophageal reflux disease (GERD)." | 9.17 | Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. ( Cundy, KC; Huff, FJ; Vakil, NB, 2013) |
| "Baclofen was associated with a significant decrease in percent upright reflux by 24-h pH monitoring and a significant improvement in belching, regurgitation and overall symptom score." | 9.16 | Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study. ( Armbruster, SP; Cossentino, MJ; Lake, JM; Mann, K; Maydonovitch, C; Wong, RK, 2012) |
| "Nine healthy volunteers and nine heartburn patients underwent two 2-h studies of combined MII/pH in right lateral decubitus after a refluxogenic meal in random order: on placebo and after baclofen 40 mg p." | 9.10 | Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. ( Castell, DO; Katz, PO; Tutuian, R; Vela, MF, 2003) |
| "Thirteen treatment-naive heartburn-prevalent GERD patients underwent two AP studies, after pretreatment with baclofen 40 mg or placebo 30 minutes preprandially." | 6.82 | Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. ( Boecxstaens, V; Broers, C; Pauwels, A; Scarpellini, E; Tack, J; Vos, R, 2016) |
| "Enrolled patients had GERD symptoms at least three times a week and 20 reflux episodes on impedance/pH monitoring over a period of 2 h." | 6.75 | Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. ( Agrawal, A; Castell, D; Gerson, LB; Hila, A; Hirota, WK; Huff, FJ; Lal, R; Luo, W; Reilley, S, 2010) |
| "Patients who were referred to Veterans Affairs (VA) gastroenterology clinics for PPI-refractory heartburn received 20 mg of omeprazole twice daily for 2 weeks, and those with persistent heartburn underwent endoscopy, esophageal biopsy, esophageal manometry, and multichannel intraluminal impedance-pH monitoring." | 5.30 | Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. ( Biswas, K; Castell, DO; Chan, BS; Chey, WD; Davis-Karim, A; Dunbar, KB; Fernando, RS; Gellad, ZF; Genta, RM; Ghaferi, AA; Huang, GD; Hunter, JG; Jackson, CS; Jones, KM; Kaz, AM; Kim, AW; Kim, T; Lagoo-Deenadayalan, S; Laine, L; Lee, R; Lieberman, D; Lo, WK; Mashimo, H; Melton, SD; Murthy, UK; Paski, SC; Pearl, JP; Pham, TH; Provenzale, D; Rubenstein, JH; Sanchez, VM; Serpi, T; Smith, BR; Souza, RF; Spechler, SJ; Tatum, RP; von Rosenvinge, EC; Wallen, JM; Warren, SR, 2019) |
| "The intensity of heartburn symptom in response to esophageal acid infusion was significantly greater with baclofen than the placebo (P = 0." | 5.30 | Gamma-aminobutyric acid receptor type B agonist baclofen inhibits acid-induced excitation of secondary peristalsis but not heartburn sensation. ( Chen, CL; Hung, JS; Lei, WY; Liu, TT; Wong, MW; Yi, CH, 2019) |
| "Arbaclofen placarbil is a pro-drug of the gamma-aminobutyric acid-B agonist R-baclofen that has been shown to reduce reflux episodes in patients with gastro-oesophageal reflux disease (GERD)." | 5.17 | Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. ( Cundy, KC; Huff, FJ; Vakil, NB, 2013) |
| "Baclofen was associated with a significant decrease in percent upright reflux by 24-h pH monitoring and a significant improvement in belching, regurgitation and overall symptom score." | 5.16 | Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study. ( Armbruster, SP; Cossentino, MJ; Lake, JM; Mann, K; Maydonovitch, C; Wong, RK, 2012) |
| "It has been shown that arbaclofen placarbil (AP) inhibits reflux in gastroesophageal reflux disease (GERD) following single oral dosing." | 5.15 | Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. ( Bian, A; Huff, FJ; Jones, DS; Stamler, D; Vakil, NB, 2011) |
| "Nine healthy volunteers and nine heartburn patients underwent two 2-h studies of combined MII/pH in right lateral decubitus after a refluxogenic meal in random order: on placebo and after baclofen 40 mg p." | 5.10 | Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. ( Castell, DO; Katz, PO; Tutuian, R; Vela, MF, 2003) |
| "Thirteen treatment-naive heartburn-prevalent GERD patients underwent two AP studies, after pretreatment with baclofen 40 mg or placebo 30 minutes preprandially." | 2.82 | Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. ( Boecxstaens, V; Broers, C; Pauwels, A; Scarpellini, E; Tack, J; Vos, R, 2016) |
| "Enrolled patients had GERD symptoms at least three times a week and 20 reflux episodes on impedance/pH monitoring over a period of 2 h." | 2.75 | Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. ( Agrawal, A; Castell, D; Gerson, LB; Hila, A; Hirota, WK; Huff, FJ; Lal, R; Luo, W; Reilley, S, 2010) |
| " Twice-daily dosing of PPI for inadequate gastric acid suppression and the administration of H2-receptor antagonist before bedtime for nocturnal acid reflux, is effective in most cases." | 2.44 | [Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor]. ( Iwakiri, K; Kawami, N; Kotoyori, M; Sakamoto, C; Sano, H; Tanaka, Y, 2007) |
Research
Studies (10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Spechler, SJ | 1 |
| Hunter, JG | 1 |
| Jones, KM | 1 |
| Lee, R | 1 |
| Smith, BR | 1 |
| Mashimo, H | 1 |
| Sanchez, VM | 1 |
| Dunbar, KB | 1 |
| Pham, TH | 1 |
| Murthy, UK | 1 |
| Kim, T | 1 |
| Jackson, CS | 1 |
| Wallen, JM | 1 |
| von Rosenvinge, EC | 1 |
| Pearl, JP | 1 |
| Laine, L | 1 |
| Kim, AW | 1 |
| Kaz, AM | 1 |
| Tatum, RP | 1 |
| Gellad, ZF | 1 |
| Lagoo-Deenadayalan, S | 1 |
| Rubenstein, JH | 1 |
| Ghaferi, AA | 1 |
| Lo, WK | 1 |
| Fernando, RS | 1 |
| Chan, BS | 1 |
| Paski, SC | 1 |
| Provenzale, D | 1 |
| Castell, DO | 2 |
| Lieberman, D | 1 |
| Souza, RF | 1 |
| Chey, WD | 1 |
| Warren, SR | 1 |
| Davis-Karim, A | 1 |
| Melton, SD | 1 |
| Genta, RM | 1 |
| Serpi, T | 1 |
| Biswas, K | 1 |
| Huang, GD | 1 |
| Wong, MW | 1 |
| Hung, JS | 1 |
| Liu, TT | 1 |
| Yi, CH | 1 |
| Lei, WY | 1 |
| Chen, CL | 1 |
| Vakil, NB | 2 |
| Huff, FJ | 3 |
| Cundy, KC | 1 |
| Scarpellini, E | 1 |
| Boecxstaens, V | 1 |
| Broers, C | 1 |
| Vos, R | 1 |
| Pauwels, A | 1 |
| Tack, J | 1 |
| Gerson, LB | 1 |
| Hila, A | 1 |
| Hirota, WK | 1 |
| Reilley, S | 1 |
| Agrawal, A | 1 |
| Lal, R | 1 |
| Luo, W | 1 |
| Castell, D | 1 |
| Bian, A | 1 |
| Jones, DS | 1 |
| Stamler, D | 1 |
| Cossentino, MJ | 1 |
| Mann, K | 1 |
| Armbruster, SP | 1 |
| Lake, JM | 1 |
| Maydonovitch, C | 1 |
| Wong, RK | 1 |
| Vela, MF | 1 |
| Tutuian, R | 1 |
| Katz, PO | 1 |
| Iwakiri, K | 1 |
| Kawami, N | 1 |
| Tanaka, Y | 1 |
| Sano, H | 1 |
| Kotoyori, M | 1 |
| Sakamoto, C | 1 |
| Fass, R | 1 |
Clinical Trials (3)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors[NCT01265550] | Phase 3 | 366 participants (Actual) | Interventional | 2012-08-13 | Completed | ||
| Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program[NCT03719170] | 208,266 participants (Actual) | Interventional | 2019-09-16 | Completed | |||
| A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)[NCT00978016] | Phase 2 | 460 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Number of Enrolled Participants With Achalasia
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 2 |
Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 3 |
Number of Enrolled Participants With Anxiety and/or Depression
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 125 |
Number of Enrolled Participants With Aperistalsis
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
Number of Enrolled Participants With Belching Disorders
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 130 |
Number of Enrolled Participants With Candida Esophagitis.
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 3 |
Number of Enrolled Participants With Chronic Idiopathic Nausea
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 51 |
Number of Enrolled Participants With Cyclic Vomiting Syndrome
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 86 |
Number of Enrolled Participants With Distal Esophageal Spasm
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 3 |
Number of Enrolled Participants With Eosinophilic Esophagitis
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 16 |
Number of Enrolled Participants With Esophageal Ulceration.
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
Number of Enrolled Participants With Functional Bloating
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 8 |
Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 13 |
Number of Enrolled Participants With Functional Diarrhea
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 4 |
Number of Enrolled Participants With Functional Dysphagia
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 7 |
Number of Enrolled Participants With Functional Gallbladder Disorder
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 1 |
Number of Enrolled Participants With Functional Heartburn
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 221 |
Number of Enrolled Participants With Functional Vomiting
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 32 |
Number of Enrolled Participants With Gastric Outlet Obstruction
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
Number of Enrolled Participants With Globus
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
Number of Enrolled Participants With Hypertensive Peristalsis
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 3 |
Number of Enrolled Participants With Ineffective Esophageal Motility
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 1 |
Number of Enrolled Participants With Irritable Bowel Syndrome
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 152 |
Number of Enrolled Participants With Jackhammer Esophagus
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 8 |
Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 0 |
Number of Enrolled Participants With Nutcracker Esophagus
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 2 |
Number of Enrolled Participants With Rapid Contraction
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 2 |
Number of Enrolled Participants With Reflux Esophagus.
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 4 |
Number of Enrolled Participants With Unspecified Functional Bowel Disorder
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 56 |
Number of Enrolled Participants With Weak Peristalsis I
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 10 |
Number of Enrolled Participants With Weak Peristalsis II
(NCT01265550)
Timeframe: Screening
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled | 9 |
Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months
"Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months.~Failure; <50% improvement in the baseline GERD-HRQL score at 12 months or:~For patients randomized to Surgical Treatment: a.<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit.~For patients randomized to Active Medical or Placebo Medical Treatment:~a.inability to tolerate both study medications or b.For patients treated with desipramine, i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit." (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 7 |
| Surgical Treatment Group | 18 |
| Placebo Medical Treatment Group | 3 |
Number of Successful Participants With Anxiety and/or Depression.
Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 2 |
| Surgical Treatment Group | 5 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Participants With Belching Disorders
Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 3 |
| Surgical Treatment Group | 12 |
| Placebo Medical Treatment Group | 2 |
Number of Successful Participants With Chronic Idiopathic Nausea
Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 3 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Participants With Cyclic Vomiting Syndrome
Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 1 |
| Surgical Treatment Group | 7 |
| Placebo Medical Treatment Group | 1 |
Number of Successful Participants With Functional Bloating
Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 1 |
| Surgical Treatment Group | 1 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin
Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Participants With Functional Diarrhea
Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Participants With Functional Dysphagia
Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Participants With Functional Gallbladder Disorder
Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Participants With Functional Heartburn
Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 7 |
| Surgical Treatment Group | 14 |
| Placebo Medical Treatment Group | 3 |
Number of Successful Participants With Functional Vomiting
Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 1 |
| Surgical Treatment Group | 1 |
| Placebo Medical Treatment Group | 1 |
Number of Successful Participants With Globus
Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 0 |
| Surgical Treatment Group | 0 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Participants With Irritable Bowel Syndrome
Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 3 |
| Surgical Treatment Group | 10 |
| Placebo Medical Treatment Group | 3 |
Number of Successful Participants With Unspecified Functional Bowel Disorder
Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Medical Treatment Group | 2 |
| Surgical Treatment Group | 5 |
| Placebo Medical Treatment Group | 0 |
Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 14 |
Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 15 |
Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 18 |
Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.
(NCT01265550)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgical Treatment Group | 14 |
Reviews
1 review available for baclofen and Pyrosis
| Article | Year |
|---|---|
[Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor].
Topics: Aryl Hydrocarbon Hydroxylases; Baclofen; Cytochrome P-450 CYP2C19; Diet; Drug Administration Schedul | 2007 |
Trials
8 trials available for baclofen and Pyrosis
| Article | Year |
|---|---|
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn.
Topics: Adult; Baclofen; Desipramine; Drug Resistance; Drug Therapy, Combination; Female; Fundoplication; Ga | 2019 |
Gamma-aminobutyric acid receptor type B agonist baclofen inhibits acid-induced excitation of secondary peristalsis but not heartburn sensation.
Topics: Adult; Baclofen; Double-Blind Method; Esophageal Motility Disorders; Esophagus; Female; GABA-B Recep | 2019 |
Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors.
Topics: Adult; Baclofen; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esoph | 2013 |
Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms.
Topics: Adult; Baclofen; Double-Blind Method; Drug Administration Schedule; Esophageal Sphincter, Lower; Eso | 2016 |
Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease.
Topics: Adult; Baclofen; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Esophage | 2010 |
Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Baclofen; Dizziness; Double-Blind Method; Drug Administration Schedule; Fatigue; Female | 2011 |
Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux--a randomised prospective study.
Topics: Adult; Baclofen; Chest Pain; Double-Blind Method; Eructation; Esophageal pH Monitoring; Female; GABA | 2012 |
Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH.
Topics: Adolescent; Adult; Aged; Baclofen; Electric Impedance; Female; GABA Agonists; Gastric Acid; Gastric | 2003 |
Other Studies
1 other study available for baclofen and Pyrosis
| Article | Year |
|---|---|
Persistent heartburn in a patient on proton-pump inhibitor.
Topics: Acupuncture Therapy; Adult; Analgesics; Anti-Ulcer Agents; Baclofen; Bile Reflux; Bilirubin; Electri | 2008 |